Development of prophylactic vaccines against HIV-1

The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiffner, Torben, Sattentau, Quentin J, Dorrell, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722125/
https://www.ncbi.nlm.nih.gov/pubmed/23866844
http://dx.doi.org/10.1186/1742-4690-10-72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722125/
https://www.ncbi.nlm.nih.gov/pubmed/23866844
http://dx.doi.org/10.1186/1742-4690-10-72

Ejemplares similares